当前位置： SCI文献检索 > BREAST CANCER RESEARCH AND TREATMENT期刊下所有文献 > Association of depression and anxiety disorder with the risk of mortality in breast cancer: A National Health Insurance Service study in Korea.

Association of depression and anxiety disorder with the risk of mortality in breast cancer: A National Health Insurance Service study in Korea.

Abstract：

PURPOSE:To examine whether depression, anxiety disorder, and their co-occurrence would increase the risk of mortality in patients with breast cancer, and whether antidepressant treatment would reduce the same. METHODS:Data were retrieved from the database of the Korean National Health Insurance Service. Of 145,251 patients diagnosed with breast cancer between 2007 and 2014, 20,870 patients diagnosed with depression or anxiety disorder one year before breast cancer diagnosis were excluded. Thus, data of 124,381 patients were included in this study. RESULTS:Depression and anxiety disorder were associated with an increased risk of mortality [Hazard Ratio (HR) 1.26, 95% CI 1.18-1.36; HR 1.14, 95% CI 1.08-1.22, respectively] and their co-occurrence further increased the risk (HR = 1.38, 95% CI 1.24-1.54). Antidepressant treatment was related to a reduced risk of mortality. Compared to patients without any psychiatric comorbidity with no antidepressant treatment, the mortality risk increased in patients with either psychiatric comorbidity or both, but the risk seemed to attenuate with antidepressant treatments. CONCLUSION:The current findings suggest that psychiatric comorbidities are markers of increased mortality risk in patients with breast cancer, and antidepressant treatment may attenuate the risk. This underscores the need for screening and treating depression and anxiety disorders to improve survival in patients with breast cancer.

journal_name

Breast Cancer Res Treat

journal_title

Breast cancer research and treatment

authors

Shim EJ,Lee JW,Cho J,Jung HK,Kim NH,Lee JE,Min J,Noh WC,Park SH,Kim YS

doi

10.1007/s10549-019-05479-3

subject

Has Abstract

pub_date

2020-01-01 00:00:00

pages

491-498

issue

2

eissn

0167-6806

issn

1573-7217

pii

10.1007/s10549-019-05479-3

journal_volume

179

pub_type

杂志文章

相关文献

BREAST CANCER RESEARCH AND TREATMENT文献大全
  • Liarozole fumarate (R85246): a novel imidazole in the treatment of receptor positive postmenopausal metastatic breast cancer.

    abstract：:This phase II study of liarozole fumarate (R85246, liarozole), a novel imidazole with retinomimetic and aromatase inhibitory effects, was designed to determine the efficacy and tolerability in postmenopausal women with advanced breast cancer in progression, to correlate these effects with hormonal levels, and to evalu...

    journal_title：Breast cancer research and treatment

    pub_type： 临床试验,杂志文章

    doi：10.1023/a:1006320122711

    authors： Goss PE,Oza A,Goel R,Nabholtz JM,De Coster R,Bruynseels J,Reid C,Wadden N,Crump M,Tye LM

    更新日期：2000-01-01 00:00:00

  • Refinement of breast cancer risk prediction with concordant leading edge subsets from prognostic gene signatures.

    abstract：:Several prognostic signatures have been identified for breast cancer. However, these signatures vary extensively in their gene compositions, and the poor concordance of the risk groups defined by the prognostic signatures hinders their clinical applicability. Breast cancer risk prediction was refined with a novel appr...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-014-3104-6

    authors： Huang CC,Tu SH,Lien HH,Huang CS,Huang CJ,Lai LC,Tsai MH,Chuang EY

    更新日期：2014-09-01 00:00:00

  • Are there racial differences in breast cancer treatments and clinical outcomes for women treated at M.D. Anderson Cancer Center?

    abstract：PURPOSE:To determine the influence of race on breast cancer treatment and on recurrence and breast cancer specific death. PATIENTS AND METHODS:The study population consisted of 6,054 African-American or white women who were diagnosed with breast cancer and received at least one of the treatments including mastectomy o...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-006-9337-2

    authors： Shen Y,Dong W,Esteva FJ,Kau SW,Theriault RL,Bevers TB

    更新日期：2007-05-01 00:00:00

  • Pertuzumab, trastuzumab, and docetaxel for Chinese patients with previously untreated HER2-positive locally recurrent or metastatic breast cancer (PUFFIN): a phase III, randomized, double-blind, placebo-controlled study.

    abstract：PURPOSE:The Chinese bridging study PUFFIN (NCT02896855) aimed to assess consistency of efficacy with CLEOPATRA (NCT00567190), investigating pertuzumab with trastuzumab and docetaxel versus placebo, trastuzumab, and docetaxel in patients with previously untreated HER2-positive locally recurrent or metastatic breast canc...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-020-05728-w

    authors： Xu B,Li W,Zhang Q,Shao Z,Li Q,Wang X,Li H,Sun T,Yin Y,Zheng H,Feng J,Zhang H,Lei G,Restuccia E

    更新日期：2020-08-01 00:00:00

  • Safety of zoledronic acid and incidence of osteonecrosis of the jaw (ONJ) during adjuvant therapy in a randomised phase III trial (AZURE: BIG 01-04) for women with stage II/III breast cancer.

    abstract：:The AZURE trial is an ongoing phase III, academic, multi-centre, randomised trial designed to evaluate the role of zoledronic acid (ZOL) in the adjuvant therapy of women with stage II/III breast cancer. Here, we report the safety and tolerability profile of ZOL in this setting. Eligible patients received (neo)adjuvant...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,随机对照试验

    doi：10.1007/s10549-011-1429-y

    authors： Coleman R,Woodward E,Brown J,Cameron D,Bell R,Dodwell D,Keane M,Gil M,Davies C,Burkinshaw R,Houston SJ,Grieve RJ,Barrett-Lee PJ,Thorpe H

    更新日期：2011-06-01 00:00:00

  • CYP2D6 genotype is not associated with survival in breast cancer patients treated with tamoxifen: results from a population-based study.

    abstract：PURPOSE:A number of studies have tested the hypothesis that breast cancer patients with low-activity CYP2D6 genotypes achieve inferior benefit from tamoxifen treatment, putatively due to lack of metabolic activation to endoxifen. Studies have provided conflicting data, and meta-analyses suggest a small but significant ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-017-4400-8

    authors： Hertz DL,Kidwell KM,Hilsenbeck SG,Oesterreich S,Osborne CK,Philips S,Chenault C,Hartmaier RJ,Skaar TC,Sikora MJ,Rae JM

    更新日期：2017-11-01 00:00:00

  • Who may benefit from preoperative breast MRI? A single-center analysis of 1102 consecutive patients with primary breast cancer.

    abstract：:Several authors question the potential benefit of preoperative magnetic resonance imaging (MRI) against the background of possible overdiagnosis, false-positive findings, and unnecessary resections in patients with newly diagnosed breast cancer. In order to reveal a better selection of patients who should undergo preo...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-015-3556-3

    authors： Debald M,Abramian A,Nemes L,Döbler M,Kaiser C,Keyver-Paik MD,Leutner C,Höller T,Braun M,Kuhl C,Kuhn W,Schild HH

    更新日期：2015-10-01 00:00:00

  • Introduction of hsa-miR-512-3p as a new regulator of HER2 signaling pathway in breast cancer.

    abstract：PURPOSE:Dysregulation of HER2 signaling pathway in breast cancer is well documented. Our bioinformatics analysis predicted hsa-miR-512-3p (miR-512-3p) as a bona fide regulator of HER2 as well as HER3, PIK3R2, and AKT1 genes. Then, we intended to examine the effect of miR-512-3p on the predicted target genes that are in...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-020-05937-3

    authors： Mohamadzade Z,Mahjoubi F,Soltani BM

    更新日期：2021-01-01 00:00:00

  • PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer.

    abstract：PURPOSE:To determine if response to endocrine therapy of breast cancer can be predicted by either a metabolic "flare reaction" detected by positron emission tomography (PET) with 2-[(18)F]-fluoro-2-deoxyglucose (FDG), induced by an estradiol challenge, or by estrogen-receptor (ER) status, determined by PET with the est...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-008-9953-0

    authors： Dehdashti F,Mortimer JE,Trinkaus K,Naughton MJ,Ellis M,Katzenellenbogen JA,Welch MJ,Siegel BA

    更新日期：2009-02-01 00:00:00

  • PAM50 assay and the three-gene model for identifying the major and clinically relevant molecular subtypes of breast cancer.

    abstract：:It has recently been proposed that a three-gene model (SCMGENE) that measures ESR1, ERBB2, and AURKA identifies the major breast cancer intrinsic subtypes and provides robust discrimination for clinical use in a manner very similar to a 50-gene subtype predictor (PAM50). However, the clinical relevance of both predict...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-012-2143-0

    authors： Prat A,Parker JS,Fan C,Perou CM

    更新日期：2012-08-01 00:00:00

  • Secreted frizzled related protein 2 (sFRP2) decreases susceptibility to UV-induced apoptosis in primary culture of canine mammary gland tumors by NF-kappaB activation or JNK suppression.

    abstract：:Tumor formation can result from a decrease in cell death, as well as an increase in cell proliferation. In spite of the high incidence of mammary gland tumors (MGTs) in female dogs, the understanding of its etiology is still poor. Consistent with several proto-oncogenes (such as Wnt) for the mammary gland, sFRP2 is ex...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-006-9233-9

    authors： Lee JL,Chang CJ,Chueh LL,Lin CT

    更新日期：2006-11-01 00:00:00

  • Differential retention of rhodamine 123 by breast carcinoma and normal human mammary tissue.

    abstract：:We have qualitatively evaluated the retention of the fluorescent dye rhodamine 123 by malignant or non-malignant breast epithelial cells in passively-infused fresh surgical specimens. Our findings demonstrate a microscopically-visible increase in the ability of primary and metastatic tumor cells to retain the dye, as ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/BF01975444

    authors： Dairkee SH,Hackett AJ

    更新日期：1991-03-01 00:00:00

  • Radial scar on image-guided breast biopsy: is surgical excision necessary?

    abstract：PURPOSE:Radial scar's stellate appearance may mimic carcinoma mammographically and histologically. Management of radial scar (RS) found on breast core needle biopsies (CNB) ranges from excision to clinical observation due to the variation in reported upgrades to malignancy at surgical excision. We examined the upgrade ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-018-4741-y

    authors： Chou WYY,Veis DJ,Aft R

    更新日期：2018-07-01 00:00:00

  • Vorozole results in greater oestrogen suppression than formestane in postmenopausal women and when added to goserelin in premenopausal women with advanced breast cancer.

    abstract：:The high potency and selectivity of new aromatase inhibitors has translated to greater efficacy and improved tolerability in comparison with established second-line hormonal agents for advanced breast cancer in phase III clinical trials. Two pharmacological studies are reported which assess the use of one of these inh...

    journal_title：Breast cancer research and treatment

    pub_type： 临床试验,杂志文章

    doi：10.1023/a:1006289811540

    authors： Dowsett M,Doody D,Miall S,Howes A,English J,Coombes RC

    更新日期：1999-07-01 00:00:00

  • CD24 Ala57Val polymorphism predicts pathologic complete response to sequential anthracycline- and taxane-based neoadjuvant chemotherapy for primary breast cancer.

    abstract：:Overexpression of CD24 is an independent prognostic factor for breast cancer. Recently, two polymorphisms in the CD24 gene were linked to disease risk and progression in autoimmune diseases. Here, we evaluated the clinical relevance of these polymorphisms with respect to their potential to predict a pathologic complet...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,多中心研究,随机对照试验

    doi：10.1007/s10549-011-1759-9

    authors： Marmé F,Werft W,Walter A,Keller S,Wang X,Benner A,Burwinkel B,Sinn P,Hug S,Sohn C,Bretz N,Moldenhauer G,Rupp C,Rupp AK,Biakhov MY,Bottini A,Friedrichs K,Khailenko VA,Manikhas GM,Ruiz A,Sánchez-Rovira P,Santoro A

    更新日期：2012-04-01 00:00:00

  • Eukaryotic translation initiation factor 4E (eIF4E) expression is associated with breast cancer tumor phenotype and predicts survival after anthracycline chemotherapy treatment.

    abstract：:Abnormal translation of mRNAs frequently occurring during carcinogenesis is among the mechanisms that can affect the expression of proteins involved in tumor development and progression. Eukaryotic initiation factor eIF4E is a key regulator of translation of many cancer-related transcripts and its expression is altere...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-013-2671-2

    authors： Heikkinen T,Korpela T,Fagerholm R,Khan S,Aittomäki K,Heikkilä P,Blomqvist C,Carpén O,Nevanlinna H

    更新日期：2013-08-01 00:00:00

  • Specific transcriptional response of four blockers of estrogen receptors on estradiol-modulated genes in the mouse mammary gland.

    abstract：:Novel agents for the endocrine therapy of breast cancer are needed, especially in order to take advantage of the multiple consecutive responses observed in metastatic progressing breast cancer following previous hormone therapy, thus delaying the use of cytotoxic chemotherapy with its frequent poor tolerance and serio...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-012-2104-7

    authors： Calvo E,Luu-The V,Belleau P,Martel C,Labrie F

    更新日期：2012-07-01 00:00:00

  • Vegetable intake is associated with reduced breast cancer recurrence in tamoxifen users: a secondary analysis from the Women's Healthy Eating and Living Study.

    abstract：:The protective effect of vegetables on the risk of breast cancer recurrence is uncertain. We sought to evaluate the association between breast cancer recurrence and vegetable intake including analyses stratified on tamoxifen use. Experimental evidence of anti-carcinogenic activity of phytochemicals in cruciferous vege...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-010-1014-9

    authors： Thomson CA,Rock CL,Thompson PA,Caan BJ,Cussler E,Flatt SW,Pierce JP

    更新日期：2011-01-01 00:00:00

  • Diagnostic imaging and biopsy pathways following abnormal screen-film and digital screening mammography.

    abstract：:The transition from screen-film to digital mammography may have altered diagnostic evaluation of women following a positive screening examination. This study compared the use and timeliness of diagnostic imaging and biopsy for women screened with screen-film or digital mammography. Data were obtained from 35,321 posit...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,多中心研究

    doi：10.1007/s10549-013-2466-5

    authors： Hubbard RA,Zhu W,Horblyuk R,Karliner L,Sprague BL,Henderson L,Lee D,Onega T,Buist DS,Sweet A

    更新日期：2013-04-01 00:00:00

  • Patient-reported outcome after oncoplastic breast surgery compared with conventional breast-conserving surgery in breast cancer.

    abstract：INTRODUCTION:Oncoplastic breast surgery (OBS) has developed as an extension of breast-conserving surgery (BCS) in an effort to improve esthetic and functional outcome following surgery for breast cancer. The aim of the present study was to evaluate the possible benefits of OBS, as compared with BCS, with regard to heal...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-020-05544-2

    authors： Rose M,Svensson H,Handler J,Hoyer U,Ringberg A,Manjer J

    更新日期：2020-02-01 00:00:00

  • 99m-Tc-tetrofosmin scintigraphy for the evaluation of suspicious palpable and non-palpable breast lesions.

    abstract：PURPOSE:To assess the value of 99m-Tc-tetrofosmin (tetrofosmin) scintigraphy in patients with palpable and nonpalpable breast lesions. PATIENTS AND METHODS:Prospective, blinded trial. One hundred and fifty-nine consecutive patients with 163 breast lesions detected by clinical examination and mammography were included....

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1023/a:1006442622417

    authors： Obwegeser R,Berghammer P,Muellauer-Ertl S,Kubista E,Sinzinger H

    更新日期：2000-08-01 00:00:00

  • The 17q23 amplicon and breast cancer.

    abstract：:A novel region of amplification in breast tumors was recently identified on chromosome 17q23. Extensive mapping of the amplicon by Southern blotting and fluorescence in situ hybridization (FISH) in breast cancer cell lines determined that the amplicon can be up to 4 Mbp in size and may contain 50 genes. Copy number an...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,评审

    doi：10.1023/a:1023081624133

    authors： Sinclair CS,Rowley M,Naderi A,Couch FJ

    更新日期：2003-04-01 00:00:00

  • Overall survival differences between patients with inflammatory and noninflammatory breast cancer presenting with distant metastasis at diagnosis.

    abstract：:Inflammatory breast cancer (IBC) is a rare and aggressive disease. Previous studies have shown that among patients with stage III breast cancer, IBC is associated with a worse prognosis than noninflammatory breast cancer (non-IBC). Whether this difference holds true among patients with stage IV breast cancer has not b...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-015-3436-x

    authors： Fouad TM,Kogawa T,Liu DD,Shen Y,Masuda H,El-Zein R,Woodward WA,Chavez-MacGregor M,Alvarez RH,Arun B,Lucci A,Krishnamurthy S,Babiera G,Buchholz TA,Valero V,Ueno NT

    更新日期：2015-07-01 00:00:00

  • Growth kinetics of four human breast carcinomas grown in nude mice.

    abstract：:The immune-deficient nude mouse with human tumor xenografts is an appropriate model system for performing detailed growth kinetic examinations. In the present study one estrogen and progesterone receptor-negative (T60) and three receptor-positive (Br-10, MCF-7, T61) human breast cancer xenografts in nude mice were inv...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/BF01810740

    authors： Spang-Thomsen M,Rygaard K,Hansen L,Halvorsen AC,Vindeløv LL,Brünner N

    更新日期：1989-11-01 00:00:00

  • Racial differences in the familial aggregation of breast cancer and other female cancers.

    abstract：:Although breast cancer familial aggregation has been studied in Caucasians, information for African-Americans is scant. We used family cancer history from the Women's Contraceptive and Reproductive Experiences study to assess the aggregation of breast and gynecological cancers in African-American and Caucasian familie...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-004-2046-9

    authors： Simon MS,Korczak JF,Yee CL,Daling JR,Malone KE,Bernstein L,Marchbanks PA,Folger SG,McDonald JA,Norman SA,Strom BL,Deapen D,Ursin G,Burkman RT,Press MF,Schwartz AG,Spirtas R

    更新日期：2005-02-01 00:00:00

  • Mammographic density and breast cancer risk in White and African American Women.

    abstract：:Mammographic density is a strong risk factor for breast cancer, but limited data are available in African American (AA) women. We examined the association between mammographic density and breast cancer risk in AA and white women. Cases (n = 491) and controls (n = 528) were from the Carolina Breast Cancer Study (CBCS) ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章

    doi：10.1007/s10549-012-2185-3

    authors： Razzaghi H,Troester MA,Gierach GL,Olshan AF,Yankaskas BC,Millikan RC

    更新日期：2012-09-01 00:00:00

  • Femara and the future: tailoring treatment and combination therapies with Femara.

    abstract：:Long-term estrogen deprivation treatment for breast cancer can, in some patients, lead to the activation of alternate cellular pathways, resulting in the re-emergence of the disease. This is a distressing scenario for oncologists and patients, but recent intensive molecular and biochemical studies are beginning to unr...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,评审

    doi：10.1007/s10549-007-9697-2

    authors： Ellis M,Ma C

    更新日期：2007-01-01 00:00:00

  • Breast cancer prevention through modulation of endogenous hormones.

    abstract：:The use of exogenous sex-steroids for hormonal contraception is important to the way of life of many modern women. The widespread use of hormonal contraceptives represents a unique opportunity to have a substantial positive impact on women's health. The observation that users of oral combination type contraceptives ha...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,评审

    doi：10.1007/BF00666430

    authors： Spicer DV,Pike MC

    更新日期：1993-11-01 00:00:00

  • CCND1 G870A polymorphism contributes to breast cancer susceptibility: a meta-analysis.

    abstract：:Cyclin D1 (CCND1), a key cell cycle regulatory protein that governs the cell cycle progression from G1 to S phase, can promote cell proliferation or induce growth arrest and apoptosis. Since the identification of a well-characterized functional polymorphism, G870A in exon 4 of CCND1, several molecular epidemiological ...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,meta分析

    doi：10.1007/s10549-008-0195-y

    authors： Lu C,Dong J,Ma H,Jin G,Hu Z,Peng Y,Guo X,Wang X,Shen H

    更新日期：2009-08-01 00:00:00

  • The histopathological and molecular features of breast carcinoma with tumour budding-a systematic review and meta-analysis.

    abstract：PURPOSE:Tumour budding (TB) is an adverse histological feature in many epithelial cancers. It is thought to represent epithelial-mesenchymal transition, a key step in the metastatic process. The significance of TB in breast carcinoma (BC) remains unclear. The aim of this study is to investigate the relationship between...

    journal_title：Breast cancer research and treatment

    pub_type： 杂志文章,评审

    doi：10.1007/s10549-020-05810-3

    authors： Lloyd AJ,Ryan ÉJ,Boland MR,Elwahab SA,Malone C,Sweeney KJ,Barry KM,McLaughlin R,Kerin MJ,Lowery AJ

    更新日期：2020-10-01 00:00:00